Titanovo Logo
Back to Cell Types

UACC-62Homo sapiens (Human)Cancer cell line

Also known as: University of Arizona Cell Culture-62, UACC62, UACC.62, UACC 62

🤖 AI SummaryBased on 12 publications

Quick Overview

UACC-62 is a human cancer cell line used in cancer research.

Detailed Summary

UACC-62 is a human cancer cell line derived from a tumor, though the specific tissue of origin is unknown. It is part of the NCI-60 panel, a widely used collection of cancer cell lines for studying cancer biology and drug sensitivity. Research on UACC-62 has focused on its genetic and molecular characteristics, including gene expression profiles, protein expression, and metabolic activities. Studies have shown that UACC-62 exhibits specific patterns of gene expression and protein synthesis that may be relevant to its role in cancer progression and response to therapies. However, detailed information about its tissue origin, disease type, and specific cell type remains limited, highlighting the need for further characterization.

Research Applications

Cancer researchDrug sensitivity profilingGene expression analysisProtein expression profilingMetabolic studies

Key Characteristics

Part of the NCI-60 panelUsed for studying cancer biologyLimited information on tissue origin
Generated on 6/17/2025

Basic Information

Database IDCVCL_1780
SpeciesHomo sapiens (Human)
Tissue SourceSkin[UBERON:UBERON_0002097]

Donor Information

Age CategoryUnknown
SexUnknown

Disease Information

DiseaseMelanoma
LineageSkin
SubtypeMelanoma
OncoTree CodeMEL

DepMap Information

Source TypeAcademic lab
Source IDACH-000425_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimplePTENp.Pro248Thrfs*5 (c.741dupA) (c.741_742insA)Homozygous-from parent cell line UACC-62
MutationSimpleBRAFp.Val600Glu (c.1799T>A)Unspecified-PubMed=26214590

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10,11
D13S317
12
D16S539
9,12
D18S51
15
D19S433
15
D21S11
28,31
D2S1338
18,20
D3S1358
15
D5S818
10,12
D7S820
8,11
D8S1179
10,13
FGA
23
Penta D
11,12
Penta E
5,14
TH01
6,9
TPOX
8,11
vWA
16,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Genetic alterations in main candidate genes during melanoma progression.

Manca A., Botti G., Ascierto P.A., Lissia A., Cossu A., Palmieri G.

Oncotarget 9:8531-8541(2018).

DOIPubMedPMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

Mob. DNA 7:20.1-20.11(2016).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Vandesompele J.

Sci. Data 3:160052-160052(2016).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

PLoS ONE 9:E92047-E92047(2014).

DOIPubMedPMC

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Hirshfield K.M., Oltvai Z.N., Vazquez A.

Cancer Metab. 1:20.1-20.13(2013).

DOIPubMedPMC

Global proteome analysis of the NCI-60 cell line panel.";

Wilhelm M., Kuster B.

Cell Rep. 4:609-620(2013).

DOIPubMed

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

Cancer Res. 73:4372-4382(2013).

DOIPubMedPMC

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Science 336:1040-1044(2012).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

Yoon C.N., Chang Y.-T.

PLoS ONE 7:E32096-E32096(2012).

DOIPubMedPMC

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

PLoS ONE 7:E31628-E31628(2012).

DOIPubMedPMC

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Ambudkar S.V., Gottesman M.M.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).

DOIPubMedPMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

A gene expression signature of invasive potential in metastatic melanoma cells.

Baguley B.C., Eccles M.R.

PLoS ONE 4:E8461-E8461(2009).

DOIPubMedPMC

Systems-level modeling of cancer-fibroblast interaction.";

Finn S.P., Loda M., Mahmood U., Ramaswamy S.

PLoS ONE 4:E6888-E6888(2009).

DOIPubMedPMC

DNA fingerprinting of the NCI-60 cell line panel.";

Chanock S.J., Weinstein J.N.

Mol. Cancer Ther. 8:713-724(2009).

DOIPubMedPMC

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mol. Cancer Ther. 5:2606-2612(2006).

DOIPubMedPMC

HLA class I and II genotype of the NCI-60 cell lines.";

Morse H.C. 3rd, Stroncek D., Marincola F.M.

J. Transl. Med. 3:11.1-11.8(2005).

DOIPubMedPMC

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

DOIPubMed

Systematic variation in gene expression patterns in human cancer cell lines.

Botstein D., Brown P.O.

Nat. Genet. 24:227-235(2000).

DOIPubMed

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.

J. Natl. Cancer Inst. 83:757-766(1991).

DOIPubMed

Rho-mediated MRTF and YAP1 activation contributes to BRAF inhibitor resistance in Sox9High/Sox10Low melanoma cells.

Larsen S.D., Gallo K.A., Neubig R.R.

bioRxiv 2018:381806-381806(2018).

DOI

Web Resources

dtp.cancer.govstrap.nci.nih.govtcpaportal.org